Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease: A Network Meta-Analysis

@article{Zhou2019ComparativeEO,
  title={Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease: A Network Meta-Analysis},
  author={Xinbin Zhou and Jin Dai and Xiao-ming Xu and Zhijun Wang and Haibin Xu and Jie Chen and Yuangang Qiu and Wei Mao},
  journal={Angiology},
  year={2019},
  volume={70},
  pages={305 - 316}
}
Contrast-induced acute kidney injury (CI-AKI) is a common complication of iodinated contrast medium administration during cardiac catheterization. [] Key Method We systematically searched several databases (including, Embase, PubMed, the Cochrane Library, and ClinicalTrials.gov) from inception to January 31, 2018. The primary outcome was occurrence of CI-AKI in patients with CKD undergoing cardiac catheterization. Both pairwise and network meta-analysis were performed.
View on SAGE
ncbi.nlm.nih.gov
19 Citations
Background Citations
5

Figures and Tables from this paper

19 Citations

A network meta-analysis on comparative efficacy of statins focusing for prevention of contrast-induced acute kidney injury in chronic kidney disease patients undergoing percutaneus coronary intervention
TLDR
A network meta-analysis was carried out to evaluate the effect of different statins in prevention of CI-AKI and also to investigate which type and dose of statins maybe the best choice specifically in CKD patients who have higher risk.
Effect of statins on post-contrast acute kidney injury: a multicenter retrospective observational study
TLDR
Preoperative statins therapy is an independent protective factor of PC-AKI, regardless of its type, and the potential use of statins in preventing PC- AKI among those at risk is underscored.
Sodium Bicarbonate versus Statins to Prevent Contrast-induced Acute Kidney Injury: A Comprehensive Review
TLDR
The objective of this review is to compare the findings of various studies that had applied different doses of statins, sodium bicarbonate, and other agents for preventing CI-AKI.
Contrast-induced nephropathy in non-cardiac vascular procedures, a narrative review: Part 1.
TLDR
Physicians and vascular surgeons should be aware of CM-related adverse events and the potential strategies to avoid them, as well as preventive strategies and alternatives to limit iodinated CM use.
Pharmacologic Prophylaxis of Contrast-Induced Nephropathy.
Contrast-Induced Acute Kidney Injury: Review and Practical Update
TLDR
The pathophysiology, predictors, and clinical management of CI-AKI are addressed with a concise overview and a suggested association with left atrial appendage closure is suggested.
In-Hospital Bleeding in Elderly Patients With Acute Coronary Syndrome: Are Potent Antiplatelet Agents Safe?
TLDR
Ticagrelor and tirofiban should be used with caution in elderly ACS patients, as the urinary tract was the most frequent bleeding site, followed by femoral arteries.
Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know.
TLDR
Physicians should keep in mind the pivotal role of cholesterol levels in determining cardiovascular outcomes and the pleiotropic beneficial effects associated with statin use and should not miss the opportunity for cardiovascular risk reduction with aggressive statin treatment.
Contrast-Induced Nephropathy after Endovascular Aneurysm Repair, Carotid and Peripheral Interventions.
The increasing use of endovascular procedures in the last few years has led to more interventions requiring contrast media. This has led to an increase in the incidence of contrast-induced…
Kidney and contrast media: Common viewpoint of the French Nephrology societies (SFNDT, FIRN, CJN) and the French Radiological Society (SFR) following ESUR guidelines.
...
...

References

SHOWING 1-10 OF 70 REFERENCES
Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
The Role of Statins in Preventing Contrast-Induced Acute Kidney Injury
TLDR
It is uncertain whether statins should be prescribed to prevent CI-AKI in the absence of other indications, and there are also conflicting results.
Contrast-Induced Acute Kidney Injury Is Associated With Long-Term Adverse Events in Patients With Acute Coronary syndrome
TLDR
Patients with acute coronary syndrome who developed CI-AKI have worse prognosis at long-term follow-up and additional preventive treatment strategies need to be developed in this group of patients.
Contrast medium induced acute kidney injury: a narrative review
TLDR
Pre-existing CKD, intra-arterial administration and CM volume are the most important risk factors for CI-AKI, and patients should be carefully stratified before the administration of CM, to reduce the negative impact of modifiable risk factors on renal function.
Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention
TLDR
Rosuvastatin and atorvastatin have similar efficacies for preventing CIN in patients with CKD undergoing PCI, after adjusting for potential confounding risk factors.
Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography.
Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome).
Statins in prevention of contrast-induced nephropathy in patients with coronary heart disease and renal insufficiency undergoing percutaneous coronary intervention
TLDR
A short-term administration of high doses of atorvastatin before and after contrast exposure fails to decrease CIN occurrence in CHD patients with pre-existing renal insufficiency.
Pro: Contrast-induced nephropathy—should we try to avoid contrast media in patients with chronic kidney disease?
  • M. WindpesslA. Kronbichler
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2018
TLDR
Despite considerable progress in the field, the risk of CI-AKI is still high in the modern era and that CM-based imaging should be employed with great restraint in patients with CKD, and there is conceded that there is always a trade-off.
Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
...
...